NCT02288481View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Tuberculosis
Interventions
DRUG

TBA-354

TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.

OTHER

Placebo

Placebo Suspension

Trial Locations (1)

68502

Celerion, Lincoln

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT02288481 - A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter